Adverum to build new AAV manufacturing facility in NC

By The Science Advisory Board staff writers

January 8, 2021 -- Adverum Biotechnologies plans to build a new good manufacturing practice (GMP) gene therapy manufacturing facility in North Carolina to internalize its adeno-associated virus (AAV) manufacturing capabilities.

The company will invest over $80 million in the 174,000-sq-ft facility, located in Research Triangle Park. The site will house four 1,000-L bioreactors with space for further expansion. The site will create more than 200 jobs in the area and will be operational by the end of 2023.

Adverum will receive $9 million in state and local incentives to expand into North Carolina, including a job development investment grant, which provides $3 million over 12 years.

Adverum is a clinical-stage gene therapy company. Its lead candidate, ADVM-022, is a one-time intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.

ViGeneron partners with WuXi for gene therapy manufacturing
ViGeneron and WuXi Advanced Therapies have announced the formation of a strategic partnership to accelerate the clinical development of VG901, a next-generation...
Pfizer to manufacture Vivet's gene therapy
Vivet Therapeutics and Pfizer have entered into a manufacturing agreement where Pfizer will provide clinical supply for a phase I/II clinical trial evaluating...
Gyros launches new product to support cell & gene therapy manufacturing
Gyros Protein Technologies introduced a new product for adeno-associated virus vector titer determination.
Kriya establishes internal gene therapy manufacturing capacity
Kriya Therapeutics has secured a 51,000-sq-ft facility in Research Triangle Park, NC, to establish internal operational manufacturing of its pipeline...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter